UCB plans to build a $2 billion biologics manufacturing facility in the US state of Georgia. This facility will be located in the same state as UCB's US headquarters, namely Smyrna. The facility will produce biologics from UCB's portfolio and development pipeline. This is a strategic investment in the production of biologics.